Entries of Eigentler, Thomas K. on the publication server

Hassel, Jessica C. , Zimmer, Lisa, Sickmann, Thomas, Eigentler, Thomas K. , Meier, Friedegund , Mohr, Peter, Pukrop, Tobias, Roesch, Alexander, Vordermark, Dirk, Wendl, Christina and Gutzmer, Ralf (2023) Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition. Cancers 15 (13), p. 3448. Fulltext not available.

Livingstone, Elisabeth, Zimmer, Lisa, Hassel, Jessica C., Fluck, Michael, Eigentler, Thomas K., Loquai, Carmen, Haferkamp, Sebastian , Gutzmer, Ralf, Meier, Friedegund , Mohr, Peter, Hauschild, Axel, Schilling, Bastian, Menzer, Christian , Kiecker, Felix, Dippel, Edgar, Roesch, Alexander, Ziemer, Mirjana, Conrad, Beate, Körner, Silvia, Windemuth-Kieselbach, Christine, Schwarz, Leonora, Garbe, Claus, Becker, Jürgen C., Schadendorf, Dirk, Livingstone, Elisabeth, Zimmer, Lisa, Hassel, Jessica C., Fluck, Michael, Eigentler, Thomas K., Loquai, Carmen, Haferkamp, Sebastian, Gutzmer, Ralf, Meier, Friedegund, Mohr, Peter, Hauschild, Axel, Schilling, Bastian, Menzer, Christian, Kiecker, Felix, Dippel, Edgar, Roesch, Alexander, Ziemer, Mirjana, Conrad, Beate, Körner, Silvia, Simon, Jan-Christoph, Herbst, Rudolf A., Berking, Carola, Utikal, Jochen, Sell, Sabine, Martens, Uwe M., Terheyden, Patrick, Stadler, Rudolf, Windemuth-Kieselbach, Christine, Schwarz, Leonora, Garbe, Claus, Becker, Jürgen C. and Schadendorf, Dirk (2022) Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial. The Lancet 400 (10358), pp. 1117-1129. Fulltext not available.

Gutzmer, Ralf, Vordermark, Dirk, Hassel, Jessica C., Krex, Dietmar, Wendl, Christina, Schadendorf, Dirk, Sickmann, Thomas, Rieken, Stefan, Pukrop, Tobias, Höller, Christoph, Eigentler, Thomas K. and Meier, Friedegund (2020) Melanoma brain metastases – Interdisciplinary management recommendations 2020. Cancer Treatment Reviews 89, p. 102083. Fulltext not available.

Heppt, Markus V., Heinzerling, Lucie, Kähler, Katharina C., Forschner, Andrea, Kirchberger, Michael C., Loquai, Carmen, Meissner, Markus, Meier, Friedegund, Terheyden, Patrick, Schell, Beatrice, Herbst, Rudolf, Göppner, Daniela, Kiecker, Felix, Rafei-Shamsabadi, David, Haferkamp, Sebastian, Huber, Margit A., Utikal, Jochen, Ziemer, Mirjana, Bumeder, Irmgard, Pfeiffer, Christiane, Schäd, Susanne G., Schmid-Tannwald, Christoph, Tietze, Julia K., Eigentler, Thomas K. and Berking, Carola (2017) Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition. European Journal of Cancer 82, pp. 56-65. Fulltext not available.

Eigentler, Thomas K. , Gutzmer, Ralf, Hauschild, Axel, Kämpgen, Eckhart, Schadendorf, Dirk, Nashan, Dorothee, Hölzle, Erhard, Trefzer, Uwe, Becker, Jürgen C., Sunderkötter, Cord, Moll, Ingrid, Richtig, Erika, Pönitzsch, Iris, Pehamberger, Hubert, Kaufmann, Roland, Pfoehler, Claudia, Vogt, Thomas, Berking, Carola, Praxmarer, Michael and Garbe, Claus (2014) Adjuvant therapy with pegylated interferon alfa-2a (PEG-IFN) versus low-dose interferon alfa-2a (IFN) in patients with malignant melanoma in stages IIa(T3a): IIIb (AJCC 2002)—Decog-trial. Journal of Clinical Oncology 32 (15_sup), p. 9071. Fulltext not available.

Eigentler, Thomas K. , Figl, Adina, Krex, Dietmar, Mohr, Peter, Mauch, Cornelia, Rass, Knut, Bostroem, Azize, Heese, Oliver, Koelbl, Oliver, Garbe, Claus and Schadendorf, Dirk (2011) Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer 117 (8), pp. 1697-1703. Fulltext not available.